BASi Appoints Senior Contract Research Executive, D. Thomas Oakley, as Chief Operating Officer
February 15 2019 - 8:03AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) is pleased to announce that D. Thomas “Tom” Oakley has
been appointed as Chief Operating Officer of the Company, effective
as of February 11, 2019. Mr. Oakley will be responsible for leading
operations among BASi’s three sites located in West Lafayette and
Evansville, Indiana, and St. Louis, Missouri.
Mr. Oakley is a distinguished senior executive with over 20
years of strategic and operational experience in the contract
research industry. Most recently, Mr. Oakley served as Chief
Executive Officer of Seventh Wave Laboratories, and joined BASi in
July of last year when BASi acquired the operations of Seventh Wave
in order to provide broader solutions and greater scientific
expertise to its clients.
Prior to his tenure at Seventh Wave Laboratories, Mr. Oakley led
DTO Associates and served as President and COO of MPI Research,
President and CEO of ChanTest Corporation, and President and CEO of
Bridge Laboratories. He has also held leadership positions with the
Sarah Cannon Research Institute and Covance.
“I have great confidence in Tom and his ability to lead and
coordinate operations among our sites,” said Robert Leasure, Jr.,
BASi’s President and Chief Executive Officer. “We have a talented
and highly-capable team of site leaders, and Tom’s vast experience
and mentorship is a tremendous asset to us as we continue to unify
operations and grow the Company.”
Mr. Oakley is a cum laude graduate of Ripon College
where he received a BA degree in economics. He also holds an MBA in
management, finance, and accounting from the JL Kellogg Graduate
School of Management at Northwestern University. Mr. Oakley is a
veteran of the United States Army.
“I am honored to assume this role and look forward to working
with our team to accelerate the incredible momentum we are
generating with our combined operations,” said Mr. Oakley. “We hit
the ground running when we joined forces last year, and I’m excited
about the prospect of continuing to successfully grow our Company
in 2019 and beyond.”
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract
research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development
companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients’ discovery
and development objectives for improved decision-making and
accelerated goal attainment. BASi’s products focus on increasing
efficiency, improving data, and reducing the cost of taking new
drugs to market. Visit www.BASinc.com for more
information about BASi.
This release may contain forward-looking statements that are
subject to risks and uncertainties including, but not limited to,
risks and uncertainties related to changes in the market and demand
for our products and services, the development, marketing and sales
of products and services, changes in technology, industry and
regulatory standards, and various market and operating risks
detailed in the company's filings with the U.S. Securities and
Exchange Commission.
Company Contact:Jill C. BlumhoffChief Financial
OfficerPhone: 756.497.8381jblumhoff@BASinc.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024